ENCOMPASS HEALTH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.35 USD | -0.52% |
|
-2.00% | +27.92% |
Financials (USD)
| Sales 2024 * | 5.31B | Sales 2025 * | 5.78B | Capitalization | 8.64B |
|---|---|---|---|---|---|
| Net income 2024 * | 414M | Net income 2025 * | 464M | EV / Sales 2024 * | 2.08 x |
| Net Debt 2024 * | 2.42B | Net Debt 2025 * | 2.14B | EV / Sales 2025 * | 1.87 x |
| P/E ratio 2024 * |
21.2
x | P/E ratio 2025 * |
19
x | Employees | 27,209 |
| Yield 2024 * |
0.7% | Yield 2025 * |
0.7% | Free-Float | 85.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on Encompass Health Corporation
More recommendations
More press releases
| 1 day | -0.52% | ||
| 1 week | -2.00% | ||
| Current month | +2.36% | ||
| 1 month | +6.25% | ||
| 3 months | +15.09% | ||
| 6 months | +29.20% | ||
| Current year | +27.92% |
1 week
84.79
86.24
1 month
81.4587.94
Current year
65.9987.94
1 year
57.5587.94
3 years
44.3387.94
5 years
44.3389.68
10 years
30.2689.68
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Tarr
CEO | Chief Executive Officer | 62 | 92-12-31 |
Douglas Coltharp
DFI | Director of Finance/CFO | 62 | 10-05-05 |
| Chief Tech/Sci/R&D Officer | 64 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslye Katz
BRD | Director/Board Member | 69 | 13-01-24 |
| Chairman | 62 | 19-12-31 | |
| Director/Board Member | 68 | 21-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.44% | 8 M€ | 0.00% | ||
| 1.39% | 2 M€ | +10.04% | ||
| 1.09% | 231 M€ | -1.00% | ||
| 1.09% | 1 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 85.35 | -0.52% | 305,224 |
| 24-05-21 | 85.8 | -0.36% | 254,689 |
| 24-05-20 | 86.11 | +0.77% | 288,277 |
| 24-05-17 | 85.45 | +0.01% | 355,324 |
| 24-05-16 | 85.44 | -1.89% | 654,919 |
Delayed Quote Nyse, May 22, 2024 at 04:00 pm EDT
More quotes
Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides specialized rehabilitative treatment on an inpatient basis. It operates hospitals in 37 states and Puerto Rico, with concentrations in Florida and Texas. It operates 161 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. The Company provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals also treat patients with or recovering from the COVID-19 virus. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.
Calendar
2024-06-30
- Ex-dividend day
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
85.8
USD
Average target price
96.5
USD
Spread / Average Target
+12.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.92% | 8.64B | |
| -18.96% | 16.5B | |
| +3.60% | 12.57B | |
| +3.98% | 11.76B | |
| +2.88% | 10.27B | |
| -7.13% | 7.47B | |
| +6.17% | 6.74B | |
| +8.77% | 6.48B | |
| -2.79% | 4.32B | |
| +29.31% | 4.3B |
- Stock Market
- Equities
- EHC Stock
